LianBio announces $310 million crossover financing
Supported by a strong U.S. and Chinese investor syndicate including Perceptive Advisors, RA Capital, Venrock Healthcare Capital Partners and CMG-SDIC Capital
Proceeds will fund advancement of the Company’s global innovation mining platform and diversified portfolio of product candidates
SHANGHAI & PRINCETON, N.J.–(BUSINESS WIRE)–LianBio, a Chinese company focused on bringing paradigm-shifting medicines to patients in China and major Asian markets, today announced it has raised $310 million in an oversubscribed crossover financing, following its founding and initial financing provided by Perceptive Advisors.
The financing was co-led by U.S. investors RA Capital and Venrock Healthcare Capital Partners and Chinese investor CMG-SDIC Capital. Other leading specialist investors in the round included: funds and accounts managed by BlackRock, Casdin Capital, Farallon, Logos Capital, Perceptive Advisors, Pfizer Inc., Sphera Healthcare, funds and accounts advised by T. Rowe Price Associates, Inc., Tybourne Capital Management, Vida Ventures, Viking Global Investors and Wellington Management.
“We are excited to partner with this world class group of investors who share our vision of accelerating broad access to transformative medicines for patients in China and other major Asian markets. Building on the success and momentum of the Company’s recent launch, this financing provides additional support for LianBio’s efforts to contribute to China’s dynamic life sciences landscape by addressing significant unmet medical needs in the region,” said Konstantin Poukalov, Managing Director, Perceptive Advisors and Executive Chairman of LianBio. “We are proud of the management team who is rapidly realizing our vision and has proven that partnership, passion and commitment can help spur the delivery of innovative therapies to the fast-growing biopharma marketplace in China.”
With the Company’s global innovation mining platform validated by an impressive syndicate of investors, LianBio is poised to advance its business model in China and major Asian markets.
Jefferies LLC acted as exclusive placement agent for the financing.
About LianBio
LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics. For more information, please visit lianbio.com.
Contacts
Investor Contact:
Thomas Hoffmann
Solebury Trout
646-378-2931
Media Contact:
Hannah Gendel
Solebury Trout
646-378-2943
